About ACTIV

The goal of ACTIV is to develop a research strategy for prioritizing and speeding development of the most promising COVID-19 vaccines and therapeutics.

Overview

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is a public-private partnership led by the National Institutes of Health (NIH) and coordinated by the Foundation for the National Institutes of Health (FNIH) to develop a research strategy for prioritizing and speeding development of the most promising COVID-19 vaccines and treatments.

ACTIV brings together NIH with its sibling agencies in the Department of Health and Human Services, including the Biomedical Advanced Research and Development Authority (BARDA), Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA); other government agencies, including the Department of Defense (DOD) and Department of Veterans Affairs (VA); the European Medicines Agency (EMA); and representatives from academia, philanthropic organizations and biopharmaceutical companies.

The COVID-19 pandemic is an unprecedented global crisis that has been met with a swift and extraordinary response. The research community is sifting through more than 100 potential preventives and treatments. However, lack of coordination could make interpretation and comparison of the results impossible because resources, like patients for trials or testing facilities, are not unlimited. 

With limited resources, there is a need to coordinate and streamline processes to make the best use of biomedical research resources and testing of preclinical compounds. Also, there is a need to prioritize the most promising vaccine candidates and move them into clinical trials in a way that is safe and efficient. For more information, visit the NIH website.

Goals:

The goals of ACTIV are to:

  • Develop a collaborative, streamlined forum to identify preclinical treatments
  • Accelerate clinical testing of the most promising vaccines and treatments
  • Improve clinical trial capacity and effectiveness
  • Accelerate the evaluation of vaccine candidates to enable rapid authorization or approval

Submit Ideas to ACTIV

Read the FAQs for submitting clinical and preclinical candidate compounds to the NIH’s portal. Submit therapeutic candidates to ACTIV

FNIH Contact

Katherine Thompson, Director of Communications, kthompson@fnih.org

The FNIH takes research integrity very seriously. For any questions or concerns, please contact ResearchIntegrity@FNIH.org.

Publications
Prospects for a safe COVID-19 vaccine
Accelerated preclinical paths to support rapid development of COVID-19 therapeutics
ACTIVating Resources for the COVID-19 Pandemic: In vivo Models for Vaccines and Therapeutics
Accelerating development of SARS-Cov-2 vaccines: The role for controlled human infection models
Accelerating development of SARS-Cov-2 vaccines: The role for controlled human infection models
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): An unprecedented partnership for unprecedented times
A strategic approach to COVID-19 vaccine R&D
Press Release
NIH Press Release (April 19, 2021): Large clinical trial to study repurposed drugs to treat COVID-19 symptoms
Press Release
NIH Press Release (October 16, 2020): NIH begins large clinical trial to test immune modulators for treatment of COVID-19
Press Release
NIH Press Release (September 23, 2020): Fourth large-scale COVID-19 vaccine trial begins in the United States
Press Release
NIH Press Release (September 10, 2020): NIH ACTIV initiative launches adaptive clinical trials of blood-clotting treatments for COVID-19
Press Release
NIH Press Release (August 4, 2020): NIH clinical trial to test antibodies and other experimental therapeutics for mild and moderate COVID-19
Press Release
NIH Press Release (July 27, 2020): Phase 3 clinical trial of investigational vaccine for COVID-19 begins
Press Release
NIH Press Release (April 17, 2020): NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options